Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462655 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL621563 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29462653 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30670316 | 1.00 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL8933324 | 0.93 | MDM2 (0.59) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL13038839 | 0.92 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1064353 | 0.92 | MDM4 (0.49) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1064352 | 0.92 | MDM4 (0.49) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL25361805 | 0.91 | TLR2 (0.59) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL25361808 | 0.91 | TLR2 (0.59) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4339204-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012013709-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011075439-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MDM2 3224/4885MDM4 2653/4885TP53 391/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | MDM2 47/4885MDM4 438/4885TP53 19/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | MDM2 4221/4885MDM4 4738/4885TP53 4199/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | MDM2 333/4885MDM4 1200/4885TP53 88/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM2 1604/4885MDM4 1294/4885TP53 178/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.